Outcomes from studies of Antineutrophil Cytoplasm Antibody Associated Vasculitis: a systematic review by the European League Against Rheumatism systemic vasculitis task force. by Mukhtyar, C. et al.
Outcomes from studies of antineutrophil cytoplasm
antibody associated vasculitis: a systematic review
by the European League Against Rheumatism
systemic vasculitis task force
C Mukhtyar,1 O Flossmann,2 B Hellmich,3 P Bacon,4 M Cid,5 J W Cohen-Tervaert,6
W L Gross,3 L Guillevin,7 D Jayne,2 A Mahr,8 P A Merkel,8 H Raspe,9 D Scott,10
J Witter,11 H Yazici,12 R A Luqmani1, on behalf of the European Vasculitis Study Group
(EUVAS)
1 Botnar Research Centre,
University of Oxford, Oxford, UK;
2 Department of Nephrology,
Addenbrooke’s Hospital,
Cambridge, UK; 3 Department of
Rheumatology, University
Hospital of Schleswig-Holstein,
Lu¨beck, Germany; 4 Department
of Rheumatology, University of
Birmingham, Birmingham, UK;
5 Department of Internal
Medicine, Hospital Clinic,
Barcelona, Spain; 6 Division of
Clinical and Experimental
Immunology, Maastricht
University, Maastricht, The
Netherlands; 7 Department of
Internal Medicine, University of
Paris Descartes, Paris, France;
8 Vasculitis Center, Boston
University School of Medicine,
Boston, Massachusetts, USA;
9 Institute of Social Medicine,
University Hospital of Schleswig-
Holstein, Lu¨beck, Germany;
10 Department of Rheumatology,
Norfolk Hospital, Norfolk, UK;
11 United States Food and Drug
Administration, Rockville,
Maryland, USA; 12 Cerrahpasa
Medical Faculty, University of
Istanbul, Istanbul, Turkey
Correspondence to:
Dr R Luqmani, Botnar Research
Centre, University of Oxford,
Windmill Road, Oxford OX3 7LD,
UK; raashid.luqmani@noc.
anglox.nhs.uk
Accepted 23 September 2007
Published Online First
2 October 2007
ABSTRACT
Objectives: We undertook a systematic literature review
as a background to the European League Against
Rheumatism (EULAR) recommendations for conducting
clinical trials in anti-neutrophil cytoplasm antibody
associated vasculitis (AAV), and to assess the quality of
evidence for outcome measures in AAV.
Methods: Using a systematic Medline search, we
categorised the identified studies according to diagnoses.
Factors affecting remission, relapse, renal function and
overall survival were identified.
Results: A total of 44 papers were reviewed from 502
identified by our search criteria. There was considerable
inconsistency in definitions of end points. Remission rates
varied from 30% to 93% in Wegener granulomatosis
(WG), 75% to 89% in microscopic polyangiitis (MPA) and
81% to 91% in Churg–Strauss syndrome (CSS). The 5-
year survival for WG, MPA and CSS was 74–91%, 45–
76% and 60–97%. Relapse (variably defined) was
common in the first 2 years but the frequency varied: 18%
to 60% in WG, 8% in MPA, and 35% in CSS. The rate of
renal survival in WG varied from 23% at 15 months to
23% at 120 months. Methods used to assess morbidity
varied between studies. Ignoring the variations in
definitions of the stage of disease, factors influencing
remission, relapse, renal and overall survival included
immunosuppressive therapy used, type of organ involve-
ment, presence of ANCA, older age and male gender.
Conclusions: Factors influencing remission, relapse,
renal and overall survival include the type of immuno-
suppressive therapy used, pattern of organ involvement,
presence of ANCA, older age and male gender.
Methodological variations between studies highlight the
need for a consensus on terminology and definitions for
future conduct of clinical studies in AAV.
Outcome measures in primary small vessel
vasculitis help to describe the natural history of
treated disease. Cyclophosphamide and gluco-
corticoids have reduced mortality in antineutro-
phil cytoplasm antibody (ANCA) associated
vasculitides (AAV), although cure remains
uncommon.1 The 5-year survival of treated AAV
is over 70%,2–5 but relapse and low grade persistent
disease result in poor quality survival.4 6–8 There is
an increased focus on preserving target organ
function.3 9 10
Terms used to describe and quantify different
disease states have been inconsistent.
Methodological agreement is important to enable
inter-study comparison, and enable uniform man-
agement in future studies.
We undertook a systematic literature review to
define disease specific outcomes in primary sys-
temic vasculitis, and the factors affecting them. We
concentrated on remission, relapse, renal survival
and mortality. This systematic review forms the
basis of recently published recommendations for
conducting clinical studies in vasculitis.11
METHODS
Search methods
We identified the following medical subject head-
ings (MeSH) in the indexing database of Medline
through PubMed to construct our search:
‘‘Antibodies, Antineutrophil cytoplasmic’’,
‘‘Vasculitis’’, ‘‘Wegener Granulomatosis’’ (WG),
‘‘Churg–Strauss Syndrome’’ (CSS), ‘‘Epidemiologic
Study Characteristics’’, ‘‘Evaluation Studies’’ and
‘‘Study characteristics’’. ‘‘Microscopic polyangiitis’’
(MPA) is not a MeSH term, therefore it was used
as a free text phrase to be used in ‘‘all fields’’. The
search identified 832 citations, excluding case
reports. These were limited by the terms
‘‘Adult’’ and ‘‘Abstracts’’ to 502 results, but there
were no limits by time or language. A search of
the Cochrane library did not produce any addi-
tional papers. No manual searching of papers was
performed.
Selection criteria
From 502 papers identified, 44 were selected using
the following criteria:
c .20 patients per cohort/arm of a study.
c Disease specific subanalysis in heterogeneous
cohorts (one paper did not meet this criterion,
but was included because the cohort had 94%
homogeneity).12 Papers were ignored if the
patient population was defined by their ser-
ological status only, without a specific diag-
nosis.
c Relevant outcome data.
c Multivariate analysis for risk factors affecting
the outcomes.
c Elimination of duplicate data.
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Data analysis
Patients were classified as WG, MPA and CSS as described in the
articles. The identified risk factors for outcomes have been
awarded a level of evidence according to European League
Against Rheumatism (EULAR) standardised operating proce-
dures.13 We discussed the variability in terminology, outcomes
and risk factors affecting the outcomes.
RESULTS
Methodological quality of the studies
A total of 44 papers met the selection criteria; 25 were
retrospective studies. Of the 19 prospective studies, 6 were
randomised controlled trials.12 14–18 Three of these trials had
heterogeneous cohorts,12 14 18 and only one had disease specific
analysis.18
Wegener granulomatosis
Remission
The remission rate for WG (table 1) ranges from 30% to 93%
depending on the definition of remission and remission
induction therapy.1 3 12 15 19–23 The definition of remission varied
from ‘‘commencement of clinical improvement’’, to ‘‘complete
absence of disease manifestations for at least 6 months’’. In
most studies, the time to achieve remission (where stated) is less
than 6 months. The heterogeneity of remission induction
therapy and the definition of remission make this data difficult
to interpret.
Factors affecting remission
Two main factors affected remission. Firstly, in a retrospective
study, severe disease as defined by a Birmingham Vasculitis
Activity Score (BVAS) of .23, was associated with an increased
likelihood of achieving remission independent of treatment
intensity; relative hazard (RH) 2.94, 95% CI 1.48 to 5.85, level of
evidence = 3.23 This finding may reflect increased responsiveness
of severe disease to immunosuppression. Patients with higher
activity have poorer survival.24 25 It is possible to have life
threatening disease, responsive to treatment. Subsequent
studies have not re-examined this relationship.
Secondly, in a retrospective cohort, each 1-point increase in
the Vasculitis Damage Index (VDI) score increased treatment
resistance; odds ratio (OR) 1.53 (95% CI 1.03 to 2.27), level of
evidence = 3.23 Damage occurred early in disease,26 and its
presence may have influenced the definition of remission in
this study, but it is likely that damage makes disease less
responsive to therapy.
Relapse
Relapse was common in WG (table 2). The rate (18–40% at
24 months) and time to first relapse (15 to 29 months)
varied.1 14–17 20 23 27–32 This variability may be spurious (due to
differing definitions of relapse) or genuinely due to differing
remission maintenance therapies or the presence or absence of
risk factors for relapse (table 3).
Factors associated with relapse
Three factors were associated with relapse. The first was
treatment; receiving ,10 g (compared to >10 g) of cyclopho-
sphamide in the first 6 months was associated with an increased
relapse rate (relative risk (RR) 2.83, 95% CI 1.33 to 6.02) despite
maintenance of immunosuppression.23 Patients who tolerated
oral cyclophosphamide 2 mg/kg/day received .10 g in
6 months (10 g in 6 months = 55 mg/day). For intravenous
therapy, three regimens have been used in trials: (a) 15 mg/kg/
pulse, first three pulses twice weekly, then every 3 weeks;34 (b)
0.7 g/m2 thrice weekly;15 and (c) 0.75 g/m2/month.35
At a maximum of 1 g/pulse, only regimen (a) can deliver 10 g
of cyclophosphamide in 6 months. This regimen is being
validated in a prospective study.36
Maintaining a high dose of prednisolone (.20 mg/day) for
less than 2.75 months increases risk of relapse (RH 2.41, 95% CI
1.12 to 5.21). This supports the current use of intensive initial
therapy.
The use of adjunctive trimethoprim/sulfamethoxazole 160/
800 mg twice daily, maintained remission for longer (RR 0.32,
95% CI 0.13 to 0.79),16 but resulted in a withdrawal rate of
20%.16 However, trimethoprim/sulfamethoxazole as monother-
apy for remission maintenance had a higher relapse rate in
Table 1 Rates of remission from studies of Wegener granulomatosis (WG) with definitions of remission and the remission induction therapy
Author Study Size (n) Remission rate (%) Time to remission Remission induction therapy Definition of remission
Hoffman et al 19921 P 133 75 NA Oral daily CYC (2 mg/kg/day) + Pred
(1 mg/kg/day, tapered after 2–4 weeks)
Complete absence of disease
Reinhold-Keller et al
199419
P 43 30 NA CYC iv (mean 667 mg/m2/month) + iv
Pred 100 mg +/– oral Pred
Complete absence of disease
for 6 months
Sneller et al 199520 P 42 71 4.2 months (median) MTX (20–25 mg/week) + Pred
1 mg/kg/day
Complete absence of disease
Guillevin et al 199715 P 27 89 6 months CYC iv (0.7 g/m2 thrice weekly) + Pred
1 mg/kg/day
Clinical improvement
23 78 6 months Oral daily CYC (2 mg/kg) + Pred
1 mg/kg/day
Aasarod et al 20003 R 108 81 4 months (median) Heterogeneous regimens Complete absence of disease
Reinhold-Keller et al
200021
P 155 54 NA Heterogeneous regimens Complete absence of disease
for 3 months
Bolley et al 200022 R 38 68 NA Heterogeneous regimens Undefined
Koldingsnes and
Nossent 200323
R 52 85 NA Heterogeneous regimens Complete absence of disease
De Groot et al 2005*12 P 49 90 3 months (median) MTX (20–25 mg/week) + Pred
1 mg/kg/day
BVAS 1 = 0 and BVAS 2,2
46 93 2 months (median) Oral CYC 2 mg/kg/day + Pred
1 mg/kg/day
*There were six patients with MPA in this cohort, divided between the two arms.
BVAS, Birmingham Vasculitis Activity Score (score 1 is for active disease and score 2 is for persistent disease); CYC, cyclophosphamide; iv, intravenous; MPA, microscopic
polyangiitis; MTX, methotrexate; P, prospective; Pred, prednisolone; R, retrospective.
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comparison to conventional remission maintenance therapy (18%
at 18 months with CYC 1.5 mg/kg/day or AZA 2 mg/kg/day in
combination with prednisolone 10 mg/kg/day; 42% at 23 months
with trimethoprim/sulphamethoxazole monotherapy).14 27
The second factor was ANCA; presence of ANCA at diagnosis
conferred an increased risk of relapse (RR 2.89, 95% CI 1.12 to
7.45).16 ANCA are likely to be important in the pathogenesis
of disease;37 38 absence may represent a milder disease less prone
to relapse.
In patients who had been positive for ANCA, a fourfold rise
in cytoplasmic (C)/proteinase 3 (PR3) ANCA predicted sub-
sequent relapse (RR 42.5, 95% CI 9.48 to 180.8).29 However,
about a third of patients did not suffer a relapse.29 Aggressive
treatment solely on the basis of a rise in ANCA titres would
expose patients to unnecessary cytotoxic therapy. Persistence of
ANCA at the onset of remission has been associated with a high
risk of relapse in mixed cohorts.39 Serial ANCA testing for
guiding therapy remains controversial; a meta-analysis of 22
studies could not reach a conclusion about the value of
serial ANCA testing due to the heterogeneity in the assay
methodologies.40
The final factor was target organ involvement. Cardiac
involvement increased risk of relapse (RH 2.87, 95% CI 1.09
to 7.58; p = 0.03).23 A creatinine clearance .60 ml/min was
associated with an increased risk of relapse (RR 2.94, 95% CI
1.27 to 6.67; p = 0.01);33 perhaps due to non-renal, granuloma-
tous disease (for example otolaryngological involvement),
which is more prone to relapse.41 Chronic nasal carriage of
Staphylococcus aureus was an independent risk factor for relapse
(RR 7.16; 95% CI 1.63 to 31.50; p = 0.009).33 The presence of S
aureus may provide a nidus of inflammation required by ANCA
to produce an inflammatory response.38
Table 2 Incidence of relapse from studies of Wegener granulomatosis (WG) with definition of relapse and the remission maintenance regimen
Author Study Size (n) Relapse rate Time to relapse Maintenance regimen Definition of relapse
Hoffman et al 19921 P 98 56% at 60 months NA Heterogeneous regimen Undefined
Sneller et al 199520 P 30 36% at 29 months 29 months MTX 20–25 mg/week +
tapering Pred
Reappearance of disease
Reinhold-Keller et al
199627
P 24 42% at 13 months NA TMP + SMX (26960 mg/day) Undefined
21 29% at 23 months NA None
Stegeman et al 1996* P 41 18% at 24 months NA TMP/SMX (26960 mg/day) +
standard therapy
Reappearance of disease
40 40% at 24 months NA Placebo + standard therapy
Guillevin et al 199715 P 24 59% at 54 months NA CYC iv (0.7 g/m2 thrice
weekly) + tapering Pred
Reappearance of major disease
manifestation
Haubitz et al 199828 R 35 (with ESRD) 49% at 41 months NA Heterogeneous regimens Reappearance of disease
Boomsma et al 200029 P 100 37% at 35 months NA Heterogeneous regimens Undefined
Fauchais et al 200130 R 35 60% at 39 months NA Heterogeneous regimens Undefined
Koldingsnes and
Nossent 200323
R 52 60% at 42.5 months 18 months Heterogeneous regimens Reappearance of disease after
complete or partial remission
Langford et al 200331 P 42 52% at 32 months 15 months MTX 20–25 mg/week Reappearance of disease
Jayne et al 200314 P 92 18% at 18 months NA AZA 2 mg/kg OR CYC
1.5 mg/kg + Pred 10 mg/day
Reappearance of one major or three
minor BVAS items
WGET 2005{17 P 89 30% at 25 months NA Eta 25 mg s/c twice weekly +
standard therapy
Reappearance of an item on the BVAS/
WG
85 25% at 19 months NA Placebo + standard therapy
Pavone et al 200632 R 36 16% at 12 months NA Heterogeneous regimens Reappearance of disease requiring
immunosuppressive therapy36 26% at 24 months
Where defined, relapse was considered only after achievement of remission.
*Standard therapy was cyclophosphamide and/or prednisolone. It was not offered to all patients, there were no differences in the number of patients on standard therapy in each
arm. {Standard therapy was methotrexate or azathioprine depending on renal function, for 12 months following remission.
AZA, azathioprine; BVAS, Birmingham Vasculitis Activity Score (Score 1 is for active disease and score 2 is for persistent disease); BVAS/WG, BVAS for Wegener granulomatosis;
CYC, cyclophosphamide; ESRD, end-stage renal disease; Eta, etanercept; iv, intravenous; MTX, methotrexate; NA, not available; P, prospective; Pred, prednisolone; R, retrospective;
s/c, subcutaneous; TMP + SMX, trimethoprim + sulphamethoxazole.
Table 3 Factors associated with Wegener granulomatosis (WG) relapse with level of evidence
Risk factor Risk of relapse Level of evidence Reference
A fourfold rise in C ANCA/PR3 ANCA titre RR 42.5 (95% CI 9.48 to 180.8) 3 Boomsma et al 200029
Chronic nasal carriage of Staphylococcus aureus* RR 7.16 (95% CI 1.63 to 31.50); p = 0.009 2B Stegeman et al 199433
Creatinine clearance .60 ml/min RR 2.94 (95% CI 1.27 to 6.67); p = 0.01 3 Stegeman et al 199433
The presence of ANCA at diagnosis RR 2.89 (95% CI 1.12 to 7.45) 1B Stegeman et al 199616
Cardiac involvement at diagnosis RH 2.87 (95% CI 1.09 to 7.58); p = 0.03 3 Koldingsnes and Nossent
200323
Cumulative cyclophosphamide dose ,10 g in the first 6 months RH 2.83 (95% CI 1.33 to 6.02); p = 0.007 3 Koldingsnes and Nossent
200323
Prednisolone >20 mg/day for ,2.75 months RH 2.41 (95% CI 1.12 to 5.21); p = 0.03 3 Koldingsnes and Nossent
200323
Co-trimoxazole as adjuvant to remission maintenance therapy RR 0.32 (95% CI 0.13 to 0.79) 1B Stegeman et al 199616
*Nasal carriage of Staphylococcus aureus tended to decrease the relapse rate in Pavone et al;32 this was not statistically significant.
ANCA, antineutrophil cytoplasm antibody; C, cytoplasmic; PR3, proteinase 3; RH, relative hazard; RR, relative risk.
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The presence of these risk factors cannot be used to justify
treatment decisions.
Relapses have been classified according to severity in some
clinical trials, but there have been methodological differ-
ences.14 17 In one study,14 a major relapse was defined as the
appearance of at least one major (eg, haematuria) item; minor
relapse required the presence of three minor (eg, myalgia,
arthritis, nasal crusting) BVAS items. By contrast, in the
Wegener’s Granulomatosis Etanercept Trial (WGET), relapses
were classified as limited or severe depending on the need for
cyclophosphamide and/or reappearance of specific organ invol-
vement.17 The qualification of relapses is useful in comparing
interventions since it may make an intervention with a higher
overall relapse rate superior, if it lowers the incidence of severe,
life-threatening relapse.
Renal survival in WG
There is a progressive rise in renal mortality over time in
patients with WG. In a retrospective cohort, 7% of patients
developed end stage renal disease at 12 months; increasing to
14% at 5 years and 23% at 10 years.9 In two other studies, end
stage renal disease occurred in 19% at 38 months, and 23% at
15 months.3 10 Factors predicting progression to end stage renal
disease were as follows. Renal factors: dialysis dependence at
diagnosis (RR 3.3 (95% CI 1.3 to 8.8), p = 0.001,3 HR 4.78 (95%
CI 1.27 to 17.86), p = 0.02,9 level of evidence = 3). A rise in
serum creatinine of 100 mmol/litre (HR 1.35 (95% CI 1.11 to
1.49), p = 0.001,9 level of evidence = 3). A rise in the 24 h urinary
protein of 1 g (HR 1.50 (95% CI 1.08 to 2.07), p = 0.02,9 level of
evidence = 3.
Other factors: a fall in haemoglobin of 1 g/dl (HR 1.64 (95%
CI 1.05 to 2.57), p = 0.03,9 level of evidence 3). An increase in
age of 10 years (HR 1.47 (95% CI 0.95 to 2.24), p = 0.08,9 level of
evidence = 3).
Survival
WG is associated with higher mortality compared to the general
population (mortality risk ratio (MRR) 3.8 (95% CI 2.6 to 5.6),
MRR 4.0 for men (95% CI 2.5 to 6.3), MRR 3.4 for women
(95% CI 1.6 to 7.2)).3 The mean survival for untreated
WG is 5 months and the 2-year mortality is 93%.42
Immunosuppressive therapy has changed the outlook. In a
historical cohort of 265 patients, the median survival of 27
patients not receiving any initial immunosuppression was 4.2
years;43 however, 57 patients treated with azathioprine +/–
prednisolone and 74 patients treated with oral cyclopho-
sphamide +/– prednisolone had a median survival of 7.3 years
and 8.5 years, respectively.43 A median survival of 21.7 years was
recorded in a series of 155 treated patients.21
Factors affecting survival
There are three main factors that affect survival (table 5).
They are as follows. Age: a rise of each decade in age
increases the risk of death in patients with WG (HR 2.18,
95% CI 1.38 to 3.42, p,0.001).9 Over the age of 52 years, the
older population has a poorer survival (HR 3.4, 95% CI 1.03 to
11.21, p = 0.04).5 Two other studies, which stratified patients at
50 and 60 years, respectively, found similar results.21 55 Patients
aged .50 had a HR of 5.73 (95% CI 2.07 to 15.85) for death in a
calendar year when compared to younger patients.21 There
was no control group to prove that the increasing risk of death
was not simply a function of increasing mortality in an older
sub-group.
The second factor is target organ damage. WG has vasculitic
and granulomatous components, each of which may respond to
different treatment.56 Upper respiratory tract involvement is the
granulomatous end of the spectrum and renal involvement is
the pure vasculitis manifestation. Upper respiratory tract
involvement is associated with better survival (HR 0.31, 95%
CI 0.11 to 0.84, p = 0.02) and renal involvement with poorer
survival (HR 4.45, 95% CI 1.48 to 13.65).5 21 This would fit with
the clinical observation that vasculitic manifestations are more
acute and life-threatening than granulomatous manifestations,
which are more likely to be indolent. The presence of lung
involvement may be a risk factor for mortality (HR 3.74, 95%
CI 1.26 to 11.13),21 but this is disputed5 and can only be resolved
by larger prospective studies.
The third factor is damage. The presence of even minimal
damage is associated with a higher risk of mortality.9
This observation would correlate with data from the original
VDI validation exercise, where a comparison of 12 non-
survivors vs 47 survivors revealed that the median VDI score
Table 4 Survival in antineutrophil cytoplasm antibody associated
vasculitides (AAV)
Time WG MPA CSS
12 months 85–97% (data from six
studies including 398
patients)9 21 22 44–46
82–92% (data from
four studies including
252 patients)45–48
93–94% (data from
two studies including
155 patients)48 49
24 months 86–97% (data from two
studies including 263
patients)21 50
NA NA
60 months 69–91% (data from
seven studies including
427 patients)5 9 44–46 50 51
45–76% (data from
five studies including
217 patients)4 45–47 51
60–97% (data from
five studies including
187 patients)2 49 52–54
120 months 75–88% (data from two
studies including 211
patients)9 21
NA NA
CSS, Churg–Strauss syndrome; MPA, microscopic polyangiitis; NA, not available;
WG, Wegener granulomatosis.
Table 5 Factors affecting survival
Risk factor
Risk of death
(95% CI)
Level of
evidence Reference
Dialysis dependence at
diagnosis
HR 8.2 (2.03 to
33.11) p = 0.003
3
Koldingsnes and
Nossent 20029
VDI >1 at diagnosis HR 5.54 (1.28 to
24.05) p = 0.022
3
Koldingsnes and
Nossent 20029
Impaired renal function at
diagnosis
HR 5.10 (1.59–
10.16)
3
Reinhold-Keller et al
200021
A serum albumin level of
(30 g/litre at diagnosis
RR 4.5 (1.3 to 16) 3
Aasarod et al 20003
Renal involvement at
diagnosis*
HR 4.45 (1.48 to
13.65)
3
Reinhold-Keller et al
200021
Lung involvement at
diagnosis{
HR 3.74 (1.26 to
11.13)
3
Reinhold-Keller et al
200021
Age .52 HR 3.4 (1.03 to
11.21), p = 0.04
3
Bligny et al 20045
Age (rise of 10 years) HR 2.18 (1.38 to
3.42), p,0.001
3
Koldingsnes and
Nossent 20029
Upper respiratory tract
involvement at diagnosis{
HR 0.31 (0.11 to
0.84), p = 0.02
3
Bligny et al 20045
*Affected only univariate analysis, not multivariate analysis.5 {Did not affect survival.5
{Affected only univariate analysis, not multivariate analysis.9
HR, hazard ratio; RR, relative risk; VDI, Vasculitis Damage Index.
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for non-survivors was significantly higher that that for survivors
(7 vs 4).57
Microscopic polyangiitis
There are very few studies of MPA due to the absence of a
definition until the Chapel Hill consensus conference.58 It is
possible that previously published studies of WG may have
inadvertently included patients with MPA. These are limita-
tions of classification and we have excluded those papers that
do not describe MPA as a separate entity. We have also excluded
cohorts with renal limited vasculitis because they have the
potential to differentiate into either WG or MPA.
Remission
In two studies, remission rates for MPA were 75% and 89%.18 41
Objective inter-study comparison and with WG (table 1) cannot
be made due to differences in defining remission and variable
remission induction regimens.
Relapse
The relapse rates in MPA from three studies are 34%
at 70 months (mean time to relapse 43 months),4 41% at
32 months (mean time to relapse 22.5 months)47 and 8% at
18 months.14 The latter was directly compared to the relapse
rate in WG (18% at 18 months), demonstrating that WG has a
higher rate of relapse than MPA (level of evidence = 2B.14
Variations in trial methodology (treatment, baseline character-
istics for the cohort and definition of outcomes) hamper inter-
trial comparison.
Survival
The 1-year survival in MPA is 82–92%,45–48 and the 5-year
survival estimates are between 45% and 76%,4 45–47 51 which is
worse than in WG (RR 1.917, 1.075–3.419, p = 0.025) (table 4).59
In two separate studies, the 1-year (83% vs 85%, p = not
significant and 87% vs 97%, p,0.01) and 5-year (45% vs 76%,
p = 0.02 and 63% vs 91.5%, p,0.01) survival of MPA was lower
than WG.45 46 The survival advantage of WG may be lost
following the onset of end stage renal disease.60
The presence of significant renal insufficiency at diagnosis is
an adverse survival marker in MPA (HR 3.69, 95% CI 1.006 to
13.4) (level of evidence = 3).48
Churg–Strauss syndrome
Remission
The search yielded only two papers where Churg–Strauss
syndrome (CSS) was studied as a distinct diagnosis.2 49 Disease
specific sub-analysis for CSS was not available in other studies.
The remission rate for CSS is 81–91%.2 49
Relapse
Relapse rates in CSS increase with time; 10%, 15% and 21% at 1,
2 and 4 years in one study,2 and 27% and 35% at 1 and 2 years in
another.32 The relapse rate of CSS maybe lower than MPA (20%
vs 34%), as seen in a prospective cohort (which also included
polyarteritis nodosa (PAN)).25 Intravenous methotrexate
(0.3 mg/kg/week) and low dose prednisolone as remission
maintenance therapy resulted in a relapse rate of 48% after 4
years.6 The median time to relapse was 9 months.6 The variable
definition of relapse has an affect on the relapse rate. For
example, when defined as ‘‘reappearance of disease except
asthma and eosinophilia’’, the relapse rate was lower than
in comparison with a definition of relapse ‘‘...requiring
immunosuppression’’.2 32 Gastrointestinal involvement is a risk
factor for relapse in CSS (HR 6.75, 95% CI 1.55 to 29.52;
p = 0.011) (level of evidence = 3).32
Survival
Patient survival in CSS is 93–94% at 1 year48 49 and 60–97% at 5
years (table 4).2 49 52–54 The five factor score (proteinuria .1 g/
day, creatinine .1.58 mg/dl, gastrointestinal involvement,
cardiomyopathy, neurological involvement) was validated in a
heterogeneous cohort of CSS and PAN (which may have
included MPA),61 but did not include a CSS specific sub-
analysis. The score was indirectly validated in a later study.2
The absence of any of the five factors carries a good prognosis
(RR 0.52, 95% CI 0.42 to 0.62; p,0.03) and the presence of two
or more of the factors increases the risk of mortality (RR 1.36,
95% CI 1.10 to 1.62; p,0.001) (level of evidence = 3).2 Of the
five factors, cardiomyopathy is an independent risk factor in
CSS (HR 3.39, 95% CI 1.6 to 7.3) (level of evidence = 3)48
Proteinuria .1 g/day was not associated with adverse survival
in a prospective cohort.2
CONCLUSIONS
This literature review summarises the clinical outcomes and the
factors influencing them in studies of AAV. A small number of
manuscripts met our selection criteria, indicating a lack of good
quality research for outcome measures in AAV. There have only
been six randomised controlled trials in AAV, and only one had
disease-specific analysis. There is limited data available from
structured clinical studies for specific diseases. From the
identified papers, it is difficult to compare outcomes due to
the variation in trial regimen and differing definitions of clinical
states. The identification of risk factors was restricted to
multivariate analysis. However, most risk factors are derived
from descriptive cohorts and there have been no controlled
studies to validate them. Definitions used for inclusion of
patients varied considerably. In some instances, the data was
published prior to any international classification scheme. The
use of the Chapel Hill Consensus Conference definition58 has
helped identify a homogeneous group of patients with MPA.
The variation in methodology of the studies reviewed in this
paper formed the basis of the recommendations by EULAR/
EUVAS for conduct of studies in AAV.11 The differences
between outcomes in the studies we have discussed may be
genuine (dependent on stage of disease, organ involvement,
therapy and so on) or perceived (due to a variation in the
definition of the outcome). Future trial design should address
this variation when calculating sample sizes by stratifying
patients according to identified risk factors. The outcome
measures and results in this paper may require updating in
future when data emerges from new studies. Currently, the
recommendations and the literature search are restricted to
AAV, primarily because the majority of controlled trials and
long-term observational studies have focussed on these forms of
vasculitis. A similar approach would apply to other forms of
primary small vessel vasculitis and may lead to the development
and implementation of recommendations in these diseases in
future. Disease related damage and the quality of life of patients
with these chronic debilitating diseases are measures of
prognostic and economic importance.8 62 63 We have not
concentrated on those outcomes, but they are discussed
elsewhere.64
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